ArticleJournal of thoracic disease2016
A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough.
Article in Journal of thoracic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of Baclofen as Add-on Therapy for Refractory Gastroesophageal Reflux Disease: A Meta-analysis.Journal of clinical gastroenterology · 2025Pooled it
- Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials.Frontiers in medicine · 2023Pooled it
- Positive effect of deep diaphragmatic breathing training on gastroesophageal reflux-induced chronic cough: a clinical randomized controlled study.Respiratory research · 2024Trial
- Somatic Symptom Disorder Is Associated with Cough Hypersensitivity and Poor Response to Anti-Reflux Therapy in Patients with Gastroesophageal Reflux-Induced Chronic Cough.Journal of clinical medicine · 2026Article
- Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial.EClinicalMedicine · 2025Article
- WAO - ARIA consensus on chronic cough: Executive summary.The World Allergy Organization journal · 2025Review
- Predictive factors for neuromodulator response in patients with nonacid gastroesophageal reflux-induced chronic cough: a retrospective data analysis.Therapeutic advances in chronic disease · 2025Article
- Article
- Article
- How to diagnose GERC more effectively: reflections on post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance.BMC pulmonary medicine · 2024Article
- Pathogenesis and management of gastroesophageal reflux disease-associated cough: a narrative review.Journal of thoracic disease · 2023Review
- GERD-related chronic cough: Possible mechanism, diagnosis and treatment.Frontiers in physiology · 2022Review
- Efficacy and Safety of Ojeok-San Plus Saengmaek-San for Gastroesophageal Reflux-Induced Chronic Cough: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial.Frontiers in pharmacology · 2022Article
- Diagnostic value of reflux episodes in gastroesophageal reflux-induced chronic cough: a novel predictive indicator.Therapeutic advances in chronic disease · 2022Article
- Cough hypersensitivity in patients with metabolic syndrome: a clinical finding and its possible mechanisms.BMC pulmonary medicine · 2021Article
- Article
- Can acid exposure time replace the DeMeester score in the diagnosis of gastroesophageal reflux-induced cough?Therapeutic advances in chronic disease · 2021Article
- Sensitivity and specificity of combination of Hull airway reflux questionnaire and gastroesophageal reflux disease questionnaire in identifying patients with gastroesophageal reflux-induced chronic cough.Annals of translational medicine · 2020Article
- Perspectives on chronic cough in Korea.Journal of thoracic disease · 2020Review
- Gabapentin versus baclofen for treatment of refractory gastroesophageal reflux-induced chronic cough.Journal of thoracic disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRefractory gastroesophageal reflux-induced chronic cough (GERC) is difficult to manage. The purpose of the study is to evaluate the efficacy of a novel stepwise protocol for treating this condition.
methodsA total of 103 consecutive patients with suspected refractory reflux-induced chronic cough failing to a standard anti-reflux therapy were treated with a stepwise therapy. Treatment commences with high-dose omeprazole and, if necessary, is escalated to subsequent sequential treatment with ranitidine and finally baclofen. The primary end-point was overall cough resolution, and the secondary end-point was cough resolution after each treatment step.
resultsHigh-dose omeprazole eliminated or improved cough in 28.1% of patients (n=29). Further stepwise of treatment with the addition of ranitide yielded a favorable response in an additional 12.6% (n=13) of patients, and subsequent escalation to baclofen provoked response in another 36.9% (n=38) of patients. Overall, this stepwise protocol was successful in 77.6% (n=80) of patients. The diurnal cough symptom score fell from 3 [1] to 1 [0] (Z=6.316, P=0.000), and the nocturnal cough symptom score decreased from 1 [1] to 0 [1] (Z=-4.511, P=0.000), with a corresponding reduction in the Gastroesophageal Reflux Diagnostic Questionnaire score from 8.6±1.7 to 6.8±0.7 (t=3.612, P=0.000). Conversely, the cough threshold C2 to capsaicin was increased from 0.49 (0.49) µmol/L to 1.95 (2.92) µmol/L (Z=-5.892, P=0.000), and the cough threshold C5 was increased from 1.95 (2.92) µmol/L to 7.8 (5.85) µmol/L (Z=-5.171, P=0.000).
conclusionsSequential stepwise anti-reflux therapy is a useful therapeutic strategy for refractory reflux-induced chronic cough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.